Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors-Reference-Cited by-同舟云学术

Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors

Published:2017-12-02 Issue:4 Volume:41 Page:357-361
ISSN:0114-5916
Container-title:Drug Safety
language:en
Short-container-title:Drug Saf

Author:

Verden Abril,Dimbil Mo,Kyle Robert,Overstreet Brian,Hoffman Keith B.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Toxicology

Link

http://link.springer.com/article/10.1007/s40264-017-0622-2/fulltext.html

Reference12 articles.

1. Eli Lilly and Company. Lilly and Incyte provide update on baricitinib. 2017. https://investor.lilly.com/releasedetail.cfm?releaseid=1034247 . Accessed 25 Sep 2017.

2. European Medicines Agency. Committee for medicinal products for human use (CHMP). Draft agenda for the meeting on 17–20 July 2017. 2017. http://www.ema.europa.eu/docs/en_GB/document_library/Agenda/2017/07/WC500231582.pdf . Accessed 25 Sep 2017.

3. Hoffman KB, Dimbil M, Tatonetti NP, Kyle RF. A pharmacovigilance signaling system based on FDA regulatory action and post-marketing adverse event reports. Drug Saf. 2016;39(6):561–75.

4. Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427–36.

5. Levine JG, Tonning JM, Szarfman A. Reply: The evaluation of data mining methods for the simultaneous and systematic detection of safety signals in large databases: lessons to be learned. Br J Clin Pharmacol. 2006;61(1):105–13.

Cited by 120 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathogenesis of cutaneous lupus;Dubois' Lupus Erythematosus and Related Syndromes;2025

2. Post-marketing safety concerns with abrocitinib: a real-world pharmacovigilance analysis of the FDA adverse event reporting system;Expert Opinion on Drug Safety;2024-05-17

3. Post-marketing safety concerns with elagolix: a disproportionality analysis of the FDA adverse event reporting system;Expert Opinion on Drug Safety;2024-05-07

4. Pharmacologic Anticoagulation Is Associated With a Lower Risk of Recurrent Venous Thromboembolic Events During Janus Kinase Inhibitor Use for Patients With a Prior Thrombosis;Inflammatory Bowel Diseases;2024-05-04

5. Under the dual effect of inflammation and pulmonary fibrosis, CTD-ILD patients possess a greater susceptibility to VTE;Thrombosis Journal;2024-04-04